US Edition
News from STAT
We’ve assigned a rating of Very High factuality to STAT. You can read more about how we’ve determined STAT’s credibility and reliability as a news source here: https://ground.news/rating-system.
Information about STAT
Where is STAT located?Boston, United StatesSTAT's WebsiteSTAT's TwitterSTAT's WikipediaMedia Bias Ratings
Average Bias Rating:
Center
Center
byAllSidesCenter
byAd Fontes MediaLean Left
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top STAT News
Marijuana Legalization · United StatesPresident Donald Trump signed an executive order Thursday directing federal agencies to reclassify marijuana, loosening long-standing restrictions on the drug and marking the most consequential shift in U.S. cannabis policy in more than half a century.
See the Story
Trump order directs federal agencies to reclassify marijuana from Schedule I to Schedule III, reshaping federal drug policy
57% Center coverage: 379 sources
Transgender · United StatesThe Trump administration announced Thursday that it would begin to take steps aimed at ending transition-related care — or what the Department of Health and Human Services has termed “sex-rejecting procedures” — for minors nationwide.
See the Story
HHS Proposes Federal Rules to Restrict Gender-Affirming Care Funding for Minors
38% Left coverage: 231 sources
San Rafael · San RafaelBioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.See the Story
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
67% Center coverage: 6 sources
